Felzartamab plus lenalidomide-dexamethasone versus lenalidomide-dexamethasone for relapsed or refractory multiple myeloma: an open-label, parallel-controlled, randomised, phase 3 trial.
Free. We’ll email you when a new paper cites this one or any other paper you follow on JClub — at most one email a day. Every email has a one-tap unsubscribe.